WNY Asset Management LLC Grows Stake in Eli Lilly and Company $LLY

WNY Asset Management LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 4.6% during the 2nd quarter, Holdings Channel.com reports. The firm owned 5,189 shares of the company’s stock after purchasing an additional 227 shares during the period. WNY Asset Management LLC’s holdings in Eli Lilly and Company were worth $4,045,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter worth $27,000. Citizens National Bank Trust Department lifted its stake in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares during the period. Blume Capital Management Inc. lifted its stake in shares of Eli Lilly and Company by 46.7% during the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares during the period. IMG Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $35,000. Finally, Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company during the first quarter worth $40,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director J Erik Fyrwald acquired 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO David A. Ricks acquired 1,632 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 4,514 shares of company stock valued at $2,894,841 in the last ninety days. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Trading Down 0.6%

NYSE LLY opened at $821.60 on Wednesday. The company has a market capitalization of $777.61 billion, a PE ratio of 53.70, a P/E/G ratio of 1.23 and a beta of 0.47. The company has a fifty day moving average of $772.90 and a 200 day moving average of $769.79. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s quarterly revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s payout ratio is presently 39.22%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on LLY shares. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. JPMorgan Chase & Co. lowered their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, September 16th. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Berenberg Bank reiterated a “hold” rating and set a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Finally, The Goldman Sachs Group lifted their price objective on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $938.61.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.